Literature DB >> 25668261

Oral iron supplementation after blood donation: a randomized clinical trial.

Joseph E Kiss1, Donald Brambilla2, Simone A Glynn3, Alan E Mast4, Bryan R Spencer5, Mars Stone6, Steven H Kleinman7, Ritchard G Cable8.   

Abstract

IMPORTANCE: Although blood donation is allowed every 8 weeks in the United States, recovery of hemoglobin to the currently accepted standard (12.5 g/dL) is frequently delayed, and some donors become anemic.
OBJECTIVE: To determine the effect of oral iron supplementation on hemoglobin recovery time (days to recovery of 80% of hemoglobin removed) and recovery of iron stores in iron-depleted ("low ferritin," ≤26 ng/mL) and iron-replete ("higher ferritin," >26 ng/mL) blood donors. DESIGN, SETTING, AND PARTICIPANTS: Randomized, nonblinded clinical trial of blood donors stratified by ferritin level, sex, and age conducted in 4 regional blood centers in the United States in 2012. Included were 215 eligible participants aged 18 to 79 years who had not donated whole blood or red blood cells within 4 months.
INTERVENTIONS: One tablet of ferrous gluconate (37.5 mg of elemental iron) daily or no iron for 24 weeks (168 days) after donating a unit of whole blood (500 mL). MAIN OUTCOMES AND MEASURES: Time to recovery of 80% of the postdonation decrease in hemoglobin and recovery of ferritin level to baseline as a measure of iron stores.
RESULTS: The mean baseline hemoglobin levels were comparable in the iron and no-iron groups and declined from a mean (SD) of 13.4 (1.1) g/dL to 12.0 (1.2) g/dL after donation in the low-ferritin group and from 14.2 (1.1) g/dL to 12.9 (1.2) g/dL in the higher-ferritin group. Compared with participants who did not receive iron supplementation, those who received iron supplementation had shortened time to 80% hemoglobin recovery in both the low-ferritin (mean, 32 days, interquartile range [IQR], 30-34, vs 158 days, IQR, 126->168) and higher-ferritin groups (31 days, IQR, 29-33, vs 78 days, IQR, 66-95). Median time to recovery to baseline ferritin levels in the low-ferritin group taking iron was 21 days (IQR, 12-84). For participants not taking iron, recovery to baseline was longer than 168 days (IQR, 128->168). Median time to recovery to baseline in the higher-ferritin group taking iron was 107 days (IQR, 75-141), and for participants not taking iron, recovery to baseline was longer than 168 days (IQR, >168->168). Recovery of iron stores in all participants who received supplements took a median of 76 days (IQR, 20-126); for participants not taking iron, median recovery time was longer than 168 days (IQR, 147->168 days; P < .001). Without iron supplements, 67% of participants did not recover iron stores by 168 days. CONCLUSIONS AND RELEVANCE: Among blood donors with normal hemoglobin levels, low-dose iron supplementation, compared with no supplementation, reduced time to 80% recovery of the postdonation decrease in hemoglobin concentration in donors with low ferritin (≤26 ng/mL) or higher ferritin (>26 ng/mL). TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01555060.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25668261      PMCID: PMC5094173          DOI: 10.1001/jama.2015.119

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  20 in total

1.  Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double-blind, placebo-controlled study.

Authors:  Hartmut Radtke; Joanna Tegtmeier; Lothar Röcker; Abdulgabar Salama; Holger Kiesewetter
Journal:  Transfusion       Date:  2004-10       Impact factor: 3.157

2.  The difference between fingerstick and venous hemoglobin and hematocrit varies by sex and iron stores.

Authors:  Ritchard G Cable; Whitney R Steele; Russell S Melmed; Bryce Johnson; Alan E Mast; Patricia M Carey; Joseph E Kiss; Steven H Kleinman; David J Wright
Journal:  Transfusion       Date:  2011-10-20       Impact factor: 3.157

3.  Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration.

Authors:  Pierre-Alexandre Krayenbuehl; Edouard Battegay; Christian Breymann; Joerg Furrer; Georg Schulthess
Journal:  Blood       Date:  2011-06-24       Impact factor: 22.113

4.  Iron deficiency in blood donors: the REDS-II Donor Iron Status Evaluation (RISE) study.

Authors:  Ritchard G Cable; Simone A Glynn; Joseph E Kiss; Alan E Mast; Whitney R Steele; Edward L Murphy; David J Wright; Ronald A Sacher; Jerry L Gottschall; Leslie H Tobler; Toby L Simon
Journal:  Transfusion       Date:  2011-10-24       Impact factor: 3.157

5.  Demographic correlates of low hemoglobin deferral among prospective whole blood donors.

Authors:  Alan E Mast; Karen S Schlumpf; David J Wright; Brian Custer; Bryan Spencer; Edward L Murphy; Toby L Simon
Journal:  Transfusion       Date:  2010-04-15       Impact factor: 3.157

6.  High prevalence of subclinical iron deficiency in whole blood donors not deferred for low hemoglobin.

Authors:  A Mireille Baart; Paulus A H van Noord; Yvonne Vergouwe; Karel G M Moons; Dorine W Swinkels; Erwin T Wiegerinck; Wim L A M de Kort; Femke Atsma
Journal:  Transfusion       Date:  2012-11-26       Impact factor: 3.157

7.  Ascertainment of iron deficiency and depletion in blood donors through screening questions for pica and restless legs syndrome.

Authors:  Barbara J Bryant; Yu Ying Yau; Sarah M Arceo; Julie A Hopkins; Susan F Leitman
Journal:  Transfusion       Date:  2013-01-10       Impact factor: 3.157

8.  Iron stores in blood donors.

Authors:  T L Simon; P J Garry; E M Hooper
Journal:  JAMA       Date:  1981 May 22-29       Impact factor: 56.272

Review 9.  The effects of oral iron supplementation on cognition in older children and adults: a systematic review and meta-analysis.

Authors:  Martin Falkingham; Asmaa Abdelhamid; Peter Curtis; Susan Fairweather-Tait; Louise Dye; Lee Hooper
Journal:  Nutr J       Date:  2010-01-25       Impact factor: 3.271

Review 10.  Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors.

Authors:  Graham A Smith; Sheila A Fisher; Carolyn Doree; Emanuele Di Angelantonio; David J Roberts
Journal:  Cochrane Database Syst Rev       Date:  2014-07-03
View more
  34 in total

1.  Genetic and behavioral modification of hemoglobin and iron status among first-time and high-intensity blood donors.

Authors:  Alan E Mast; John C Langer; Yuelong Guo; Walter Bialkowski; Bryan R Spencer; Tzong-Hae Lee; Joseph Kiss; Ritchard G Cable; Donald Brambilla; Michael P Busch; Grier P Page
Journal:  Transfusion       Date:  2020-03-12       Impact factor: 3.157

2.  The operational implications of donor behaviors following enrollment in STRIDE (Strategies to Reduce Iron Deficiency in blood donors).

Authors:  Ritchard G Cable; Rebecca J Birch; Bryan R Spencer; David J Wright; Walter Bialkowski; Joseph E Kiss; Jorge Rios; Barbara J Bryant; Alan E Mast
Journal:  Transfusion       Date:  2017-07-13       Impact factor: 3.157

3.  Treating iron deficiency.

Authors:  Michelle P Zeller; Madeleine Verhovsek
Journal:  CMAJ       Date:  2016-12-19       Impact factor: 8.262

4.  Preoperative autologous blood donation in healthy bone marrow donors contributes to pre-procedure anemia.

Authors:  S P Manuel; T R Spitzer; Y Ishizawa
Journal:  Bone Marrow Transplant       Date:  2017-05-22       Impact factor: 5.483

5.  Frequent blood donations alter susceptibility of red blood cells to storage- and stress-induced hemolysis.

Authors:  Tamir Kanias; Mars Stone; Grier P Page; Yuelong Guo; Stacy M Endres-Dighe; Marion C Lanteri; Bryan R Spencer; Ritchard G Cable; Darrell J Triulzi; Joseph E Kiss; Edward L Murphy; Steve Kleinman; Mark T Gladwin; Michael P Busch; Alan E Mast
Journal:  Transfusion       Date:  2018-11-26       Impact factor: 3.157

6.  Blood donation and anemia.

Authors:  Karen L Armstrong
Journal:  Can Fam Physician       Date:  2016-09       Impact factor: 3.275

7.  International forum: an investigation of iron status in blood donors.

Authors:  Tomislav Vuk; Karin Magnussen; Wim De Kort; Gilles Folléa; Giancarlo M Liumbruno; Harald Schennach; Giovani Vandewalle; Veerle Compernolle; Natalia Masharova; Georgia Karakatsiani; Isabella Argyrou; Vít Řeháček; Gulara Khanirzajeva; Johanna Castrén; Bruno Danic; Rachid Djoudi; Geneviève Woimant; Markus M Mueller; Constantina Politis; Stefania Vaglio; Anita Daugavvanaga; Edita Vilutytė; Jean-Claude Faber; Denise Borg-Aquilina; Peter Van Den Burg; Arlinke Bokhorst; Ryszard Pogłód; Jolanta Antoniewicz-Papis; Mario Muon; Olivia L Burta; Jana Rosochová; Polonca Mali; Miguel A Vesga; Karin Schneider; Rut Norda; Nicky Anderson
Journal:  Blood Transfus       Date:  2016-09-07       Impact factor: 3.443

8.  Oral iron and blood donation: cui bono?

Authors:  Bryan R Spencer
Journal:  Blood Transfus       Date:  2020-08-06       Impact factor: 3.443

9.  The benefits of iron supplementation following blood donation vary with baseline iron status.

Authors:  Alan E Mast; Aniko Szabo; Mars Stone; Ritchard G Cable; Bryan R Spencer; Joseph E Kiss
Journal:  Am J Hematol       Date:  2020-04-15       Impact factor: 10.047

10.  Iron supplementation limits the deleterious effects of repeated blood donation on endurance sport performance but not on iron status.

Authors:  Barbara Pachikian; Damien Naslain; Nicolas Benoit; Romain Brebels; Kristin Van Asch; Veerle Compernolle; Philippe Vandekerckhove; Louise Deldicque
Journal:  Blood Transfus       Date:  2020-07-22       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.